Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
3.855
-0.535 (-12.19%)
At close: Nov 4, 2025, 4:00 PM EST
4.390
+0.535 (13.88%)
Pre-market: Nov 5, 2025, 5:59 AM EST
Imunon Employees
Imunon had 25 employees as of December 31, 2024. The number of employees decreased by 8 or -24.24% compared to the previous year.
Employees
25
Change (1Y)
-8
Growth (1Y)
-24.24%
Revenue / Employee
n/a
Profits / Employee
-$629,830
Market Cap
9.72M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | -8 | -24.24% |
| Dec 31, 2023 | 33 | 2 | 6.45% |
| Dec 31, 2022 | 31 | 2 | 6.90% |
| Dec 31, 2021 | 29 | 2 | 7.41% |
| Dec 31, 2020 | 27 | -2 | -6.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMNN News
- 22 hours ago - IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer - GlobeNewsWire
- 5 days ago - IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting - GlobeNewsWire
- 12 days ago - IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting - GlobeNewsWire
- 15 days ago - IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer - GlobeNewsWire
- 18 days ago - IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences - GlobeNewsWire
- 21 days ago - IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress - GlobeNewsWire
- 6 weeks ago - IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift - GlobeNewsWire
- 6 weeks ago - IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research - GlobeNewsWire